AR072265A1 - Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende - Google Patents

Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende

Info

Publication number
AR072265A1
AR072265A1 ARP090102266A ARP090102266A AR072265A1 AR 072265 A1 AR072265 A1 AR 072265A1 AR P090102266 A ARP090102266 A AR P090102266A AR P090102266 A ARP090102266 A AR P090102266A AR 072265 A1 AR072265 A1 AR 072265A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkenyl
independently selected
cycloalkyl
groups
Prior art date
Application number
ARP090102266A
Other languages
English (en)
Spanish (es)
Inventor
Roberto Pellicciari
Flavio Moroni
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR072265A1 publication Critical patent/AR072265A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP090102266A 2008-06-19 2009-06-19 Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende AR072265A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7385708P 2008-06-19 2008-06-19

Publications (1)

Publication Number Publication Date
AR072265A1 true AR072265A1 (es) 2010-08-18

Family

ID=41087350

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102266A AR072265A1 (es) 2008-06-19 2009-06-19 Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende

Country Status (12)

Country Link
US (3) US8299090B2 (enExample)
EP (2) EP2896626A1 (enExample)
JP (2) JP5564495B2 (enExample)
AR (1) AR072265A1 (enExample)
AU (1) AU2009260060B2 (enExample)
CA (1) CA2728454C (enExample)
DK (1) DK2303895T3 (enExample)
ES (1) ES2530815T3 (enExample)
HK (1) HK1212698A1 (enExample)
SA (1) SA109300394B1 (enExample)
TW (1) TWI471329B (enExample)
WO (1) WO2009155402A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
JP5632368B2 (ja) * 2008-06-19 2014-11-26 ワイス・エルエルシー チエニル−およびフラニル−イソキノリノン、ならびにそれらの使用方法
BR112014000267A2 (pt) 2011-07-04 2016-09-20 Bayer Ip Gmbh utilização de isoquinolinonas, isoquinolinedionas, isoquinolinetrionas e dihidroisoquinolinonas substituídas ou, em cada caso, sais das mesmas como agentes ativos contra o stress abiótico em plantas
ES2562903T3 (es) * 2011-07-13 2016-03-09 Santen Pharmaceutical Co., Ltd Nuevo compuesto que tiene actividad inhibidora de PARP
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005745B1 (en) * 1978-05-26 1982-07-14 Gruppo Lepetit S.P.A. Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
ATE540928T1 (de) 2002-11-22 2012-01-15 Mitsubishi Tanabe Pharma Corp Isochinolinverbindungen und ihre medizinische verwendung
EP1913064B1 (en) 2005-08-01 2011-11-16 Wietek Holding GmbH Process for the recycling of plastics
EP2069351B1 (en) * 2006-06-20 2015-10-28 AbbVie Inc. Pyrazoloquinazolinones as parp inhibitors
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
JP5632368B2 (ja) * 2008-06-19 2014-11-26 ワイス・エルエルシー チエニル−およびフラニル−イソキノリノン、ならびにそれらの使用方法

Also Published As

Publication number Publication date
US20150133443A1 (en) 2015-05-14
US9265769B2 (en) 2016-02-23
TW201002725A (en) 2010-01-16
US20090318442A1 (en) 2009-12-24
JP2014122242A (ja) 2014-07-03
JP2011525185A (ja) 2011-09-15
JP5564495B2 (ja) 2014-07-30
US8906935B2 (en) 2014-12-09
AU2009260060B2 (en) 2015-01-22
EP2303895A1 (en) 2011-04-06
TWI471329B (zh) 2015-02-01
SA109300394B1 (ar) 2013-01-22
DK2303895T3 (en) 2015-01-12
ES2530815T3 (es) 2015-03-05
HK1212698A1 (en) 2016-06-17
HK1156310A1 (en) 2012-06-08
CA2728454A1 (en) 2009-12-23
EP2896626A1 (en) 2015-07-22
US20130059843A1 (en) 2013-03-07
WO2009155402A1 (en) 2009-12-23
EP2303895B1 (en) 2014-09-24
AU2009260060A1 (en) 2009-12-23
CA2728454C (en) 2017-01-17
US8299090B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
GT200500368A (es) Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
AR068051A1 (es) Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer.
AR074775A1 (es) Compuestos aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10
ES2530815T3 (es) Tiazolil y oxazolil-isoquinolinonas y métodos para usar las mismas
PE20191540A1 (es) DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA
CL2007001731A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CO6410305A2 (es) Inhibidores de poli (adp-ribosa) polimerasa (parp)
CL2007001732A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
PE20141938A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
AR101177A1 (es) Inhibidores de la syk
CY1117427T1 (el) Παραγωγο πυραζολοκινολινης ως αναστολεις pde9
AR074966A1 (es) Compuestos amino-heterociclicos
AR064010A1 (es) Inhibidores de la actividad de la akt
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
CR20140085A (es) Inhibidores de pde10 de pirimidina
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
PE20121556A1 (es) 3,6-diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina
CL2011002838A1 (es) Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos de receptores mglur2; composición farmacéutica; proceso para prepararla; y su uso en el tratamiento o la prevención de un trastorno del sistema nervioso central seleccionado de ansiedad y esquizofrenia, entre otros.
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PE20130395A1 (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
AR090005A1 (es) Imidazo[1,2-a]pirimidinas y piridinas sustituidas

Legal Events

Date Code Title Description
FG Grant, registration